Pharming Shares Sink On CHMP Rebuff For Rhucin

Shares in Pharming Group NV sank by more than 65 percent on news that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on a marketing authorization application for its lead drug, the hereditary angioedema treatment Rhucin. (BioWorld International)